Access all of the content
It was a pleasure to meet with Prof. Tobias Welte (Medizinische Hochschule, Hannover, Germany), following his keynote presentation, to continue the discussion around COVID-19 management, current vaccine approaches and promising agents in clinical development.
1. What are the major obstacles to be overcome in the investigation of management and preventative strategies for COVID-19? (0:37)
2. In your opinion, what are the most promising agents in clinical development for COVID-19 treatment? (2:47)
3. What progress has been made in the development of monoclonal antibody therapies? (5:14)
4. Could you give us a brief overview of the status of the major vaccine trials worldwide? (6:18)
5. What have we learned in terms of improving the efficiency of vaccine studies? (9:23)
Speaker disclosure: Tobias Welte has received research grants from the DFG, BMBF, EU, and WHO. He has also received lecture fees from AstraZeneca, Basilea, Biotest, Bayer, Boehringer, Berlin Chemie GSK, Infectopharm, MSD, Novartis, Pfizer, Roche and acted as an advisory board member for AstraZeneca, Basilea, Biotest, Bayer, Boehringer, Gilead, GSK, Janssens, Novartis, Pfizer and Roche.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In COVID-19
Iwein Gyselinck, ERS 2021: DAWn-AZITHRO – Azithromycin for Patients with COVID-19
TouchRESPIRATORY got the opportunity to catch up with Dr Iwein Gyselinck around the DAWn-AZITHRO trial of azithromycin antiviral therapy for patients with COVID-19. The abstract ‘Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof of concept clinical trial.’ (Presentation ID 2666) was presented at ERS International Congress 2021, 5-8 […]
Sara Tomassetti, ATS 2021: Post-COVID-19 Interstitial Lung Syndrome
We were delighted to catch up with Dr Sara Tomassetti (Careggi University Hospital, Florence, Italy) around interstitial lung changes following SARS-CoV-2 infection. The abstract ‘A Multidisciplinary Multicenter Study Evaluating Risk Factors, Prevalence and Characteristics of Post-COVID-19 Interstitial Lung Syndrome PCOILS.‘ (ABSTRACT NUMBER: A1748) was presented at ATS 2021 International Conference, 14-19 May, 2021. Questions What […]
Julie Ake, CHEST 2020 – Vaccine Candidates for COVID-19
Following her presentation at CHEST 2020, entitled ‘Current Vaccine Candidates for COVID-19: Preclinical and Clinical Data’, Julie Ake (Walter Reed Army Institute of Research, Silver Spring, MD, USA) talks to touchRESPIRATORY further about vaccines in development for COVID-19. Questions What different vaccine platforms are currently being investigated for COVID-19? (0.12) How are clinical trials being harmonised and accelerated for rapid vaccine development? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!